Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074831 | 0.92 | NAAA (0.52) | ALDH1A1TSHRHCAR2NAAAEPHX1 | |
| SCHEMBL7653360 | 0.88 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL9233388 | 0.86 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL8384168 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL1164145 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL8199745 | 0.83 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL442926 | 0.83 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL4897030 | 0.82 | ALDH1A1 (0.45) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL2251073 | 0.82 | NAAA (0.48) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL2951662 | 0.81 | ALDH1A1 (0.44) | ALDH1A1ATMTSHRHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-RE37664-E1 | Use of derivatives of N-phenl-3,4,5,6-tetrahydrophthalimide for the desiccation and abscission of plant organs | BASF AKTIENGESSELLSCHAFT (DE) | 2002-04-16 | — | — | US | disclosed |
| EP-0593425-B1 | OXIDIC HETEROGENEOUS CATALYSTS OF OSMIUM, METHOD FOR MANUFACTURING THEM AND THEIR USE IN CONVERTING OLEFINIC COMPOUNDS INTO GLYCOLS | HOECHST AG (DE) | 1994-12-28 | — | — | EP | disclosed |
| US-5045105-A | Use of derivatives of n-phenyl-3,4,5,6-tetrahydrophthalimide for the desiccation and abscission of plant organs | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-03 | — | — | US | disclosed |
| WO-1991000143-A1 | OXIDIC HETEROGENEOUS CATALYSTS OF OSMIUM, METHOD FOR MANUFACTURING THEM AND THEIR USE IN CONVERTING OLEFINIC COMPOUNDS INTO GLYCOLS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-10 | — | — | WO | disclosed |
| US-4925484-A | N-phenyltetrahydrophthalimides | BASF AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3966/4885ATM 3039/4885TSHR 4427/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3966/4885ATM 3039/4885TSHR 4427/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ALDH1A1 3872/4885ATM 2744/4885TSHR 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.